Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

HPK vs VET: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

HPK Captures Overall Composite Edge (72.5 BUY vs 71.1 BUY), While VET Leads 5–1 on Growth & Valuation Pillars

HPK Overall Winner 6-Pillar Tally: HPK 1 – 5 VET Matrix Metrics: HPK 5 – 5 VET

As of Nov 20, 2026, HighPeak Energy, Inc. (HPK) captures the overall head-to-head institutional edge over Vermilion Energy Inc. (VET) on higher Unified Composite conviction (72.5/100 BUY vs. 71.1/100 BUY) after splitting the core matrix 5–5 (led by Profitability & Quality), while VET wins 5–1 across the 6-pillar growth and valuation breakdown. HPK trades at $7.07 (24.4x Forward P/E, 18.8% operating margin) versus VET at $10.25 (17.4x Forward P/E, -0.7% operating margin).

  • Growth vs. Quality Trade-Off: HPK earns the overall head-to-head edge with a stronger Unified Composite Score (72.5/100 BUY vs. VET 71.1/100 BUY) and -0.85β · 94% Vol risk profile, whereas VET leads top-line expansion (+30.4% YoY revenue growth, 3.58x PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: HPK is currently in a Breakdown options structure phase (RSI 36.5); meanwhile VET is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About HPK vs VET
HPK NASDAQ Head-to-Head Winner
HighPeak Energy, Inc. Common Stock
Drilling Oil & Gas Wells
$7.07
-0.42% 1D
Market Cap $898.4M
TTM Revenue $911M
Forward P/E 24.4x
Beta / 30D Vol -0.85β · 94% Vol
Unified Composite Score
72.5 / 100 BUY
Tech 91.0 Fund 73.0 Flow 54.0 Mom 70.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 37
RSI-14: 36.5 · SMA20: $8.35 · SMA50: $8.73
VET NYSE
Vermilion Energy Inc.
Crude Petroleum & Natural Gas
$10.25
-1.06% 1D
Market Cap $1.6B
TTM Revenue $1.97B
Forward P/E 17.4x
Beta / 30D Vol -0.77β · 61% Vol
Unified Composite Score
71.1 / 100 BUY
Tech 84.0 Fund 71.0 Flow 56.0 Mom 70.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.7%), weak momentum, RSI 33
RSI-14: 33.5 · SMA20: $11.53 · SMA50: $12.01

6-Pillar Scorecard Institutional Category Breakdown (HPK 1 – 5 VET)

Columns: Metric · HPK · VET
1. Valuation Multiples VET
Forward P/E 24.4x 17.4x
Trailing P/E 32.7x 17.4x
PEG Ratio N/M 3.58x
EV / Revenue 2.1x 1.4x
2. Growth & Scale VET
Revenue Growth (YoY) +23.0% +30.4%
Earnings Growth (YoY) +215.2% -94.9%
TTM Revenue (USD) $911M $1.97B
Market Cap $898.4M $1.6B
3. Profitability & Quality HPK
Gross Margin 73.4% 64.0%
Operating Margin 18.8% -0.7%
Net Profit Margin -13.8% -24.6%
Return on Equity (ROE) -8.1% -20.1%
4. Balance Sheet & Cash Flow VET
Cash Generation (TTM) -$10M $1.31B
Cash Flow Margin -1.1% 66.5%
Net Cash / Leverage $1.04B Net Debt (0.78x D/E) $1.18B Net Debt (0.59x D/E)
Dividend Yield 0.56% 5.20%
5. Options & Positioning VET
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 109.3% (82nd %ile) 46.5% (23rd %ile)
Put/Call OI Skew 0.57x (Call-Skewed) 0.30x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat VET
OpEx & R&D Intensity 54.6% of Rev ($497M) 64.7% of Rev ($1.27B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Oil & Gas E&P Operator Oil & Gas E&P Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: HPK (5) vs VET (5)
Institutional Metric HPK VET Criterion Row Edge
Market Capitalization
Scale
$898.4M $1.6B Larger Scale VET
Trailing P/E Ratio
Valuation
32.7x 17.4x Lower Multiple VET
Forward P/E Ratio
Valuation
24.4x 17.4x Lower Multiple VET
Revenue Growth (YoY)
Growth
+23.0% +30.4% Higher Growth VET
Operating Margin (TTM)
Profitability
18.8% -0.7% Higher Margin HPK
Net Profit Margin
Profitability
-13.8% -24.6% Higher Margin HPK
Return on Equity (ROE)
Capital Efficiency
-8.1% -20.1% Higher ROE HPK
52-Week Range Position
Momentum
39% ($4–$12) 35% ($8–$15) Stronger Trend HPK
Beta / 30D Volatility
Risk Regime
-0.85β · 94% Vol -0.77β · 61% Vol Lower Realized Risk VET
Unified Institutional Score
Composite Signal
72.5 / 100 (BUY) 71.1 / 100 (BUY) Higher Composite HPK
Trailing 12M Revenue (USD)
Operating Scale
$911M $1.97B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
73.4% 64.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 2.1x EV/Rev 3.58x PEG · 1.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$10M ($1.04B Net Debt (0.78x D/E)) $1.31B ($1.18B Net Debt (0.59x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon VET +13.14 pp
HPK: -36.93% · VET: -23.79%
3M Horizon HPK +5.22 pp
HPK: -13.04% · VET: -18.26%
6M Horizon HPK +6.73 pp
HPK: -9.94% · VET: -16.67%
1Y Horizon HPK +12.75 pp
HPK: +24.04% · VET: +11.29%

Financial Trajectory Annualized Quarterly Run-Rate Revenue & Operating Margin Trajectory (USD-Normalized)

Split-Invariant USD Revenue & Operating Margin (%)
Period HPK Revenue VET Revenue HPK Op. Margin VET Op. Margin Margin Leader
Q3 '25 $830M $1.86B 15.7% 6.7% HPK
Q4 '25 $870M $1.85B -7.5% -0.8% VET
Q1 '26 $860M $2.08B 16.7% 19.6% VET
Q2 '26 $1.09B $2.25B 30.6% 23.9% HPK
Q3 '26 $1.03B $2.44B 27.9% 25.8% HPK

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
HPK BREAKDOWN
24d in phase · OBV NEUTRAL
Current IV 109.3%
IV Percentile 82nd %ile
Put/Call OI Skew 0.57x (Call-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact HPK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VET CONSOLIDATION
48d in phase · OBV NEUTRAL
Current IV 46.5%
IV Percentile 23rd %ile
Put/Call OI Skew 0.30x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact VET Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
HPK Moat Profile Scale & Operating Efficiency Moat
Oil & Gas E&P Operator
Competes within the Oil & Gas E&P value chain with $898.4M market capitalization and 18.8% operating margin.
OpEx & R&D Reinvestment 54.6% of Rev ($497M)
90D Engineering Disclosures 0 Published
VET Moat Profile Cyclical / Execution-Driven Positioning
Oil & Gas E&P Operator
Competes within the Oil & Gas E&P value chain with $1.6B market capitalization and -0.7% operating margin.
OpEx & R&D Reinvestment 64.7% of Rev ($1.27B)
90D Engineering Disclosures 0 Published

Investor FAQ HPK vs VET Key Questions & Quantitative Answers

As of Nov 20, 2026, HighPeak Energy, Inc. (HPK) captures the overall head-to-head institutional edge over Vermilion Energy Inc. (VET) on higher Unified Composite conviction (72.5/100 BUY vs. 71.1/100 BUY) after splitting the core matrix 5–5 (led by Profitability & Quality), while VET wins 5–1 across the 6-pillar growth and valuation breakdown. HPK trades at $7.07 (24.4x Forward P/E, 18.8% operating margin) versus VET at $10.25 (17.4x Forward P/E, -0.7% operating margin). Growth vs. Quality Trade-Off: HPK earns the overall head-to-head edge with a stronger Unified Composite Score (72.5/100 BUY vs. VET 71.1/100 BUY) and -0.85β · 94% Vol risk profile, whereas VET leads top-line expansion (+30.4% YoY revenue growth, 3.58x PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: HPK is currently in a Breakdown options structure phase (RSI 36.5); meanwhile VET is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VET leads the Growth & Scale pillar: HPK posts +23.0% YoY revenue growth and +215.2% YoY earnings growth on $911M TTM revenue (73.4% gross margin, 18.8% operating margin), compared with VET at +30.4% YoY revenue growth and -94.9% YoY earnings growth on $1.97B TTM revenue (64.0% gross margin, -0.7% operating margin). Across the 5-period historical trajectory (Q3 '25 to Q3 '26), HPK cumulative revenue shifted +24.1% while VET shifted +31.2%. In operating R&D and SG&A reinvestment, HPK deploys 54.6% of Rev ($497M) (0 90-day corporate R&D disclosures) versus 64.7% of Rev ($1.27B) (0 disclosures) for VET.

VET screens cheaper on headline valuation multiples. HPK trades at 24.4x Forward P/E, 32.7x Trailing P/E, N/M PEG, and 2.1x EV/Revenue (-1.1% FCF margin), whereas VET trades at 17.4x Forward P/E, 17.4x Trailing P/E, 3.58x PEG, and 1.4x EV/Revenue (66.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against HPK (-8.1% ROE) versus VET (-20.1% ROE) capital efficiency.

In options market volatility and institutional positioning, HPK carries 109.3% implied volatility (82nd %ile, Extreme (>80th %ile)), a 0.57x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (-0.85β · 94% Vol realized risk). By comparison, VET carries 46.5% implied volatility (23rd %ile, Compressed (<25th %ile)), a 0.30x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (-0.77β · 61% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.